Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, alleging that the company made false or misleading statements regarding its gene therapy product ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [3][4]. Group 1: Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for Duchenne muscular dystrophy, including the gene therapy product ELEVIDYS [3]. Group 2: Allegations and Impact - The lawsuit claims that during the class period, Sarepta failed to disclose significant safety risks associated with ELEVIDYS, inadequacies in clinical trial protocols, and the potential for adverse events that could jeopardize regulatory approvals [3]. - On March 18, 2025, Sarepta disclosed a patient death due to acute liver failure linked to ELEVIDYS, resulting in a stock price drop of over 27% [4]. - Following an April 4, 2025 announcement regarding a review by European regulatory authorities, Sarepta's stock fell an additional 7% after halting recruitment and dosing in certain clinical trials [5]. - A second patient death was reported on June 15, 2025, leading to a 42% decline in stock price as the company suspended shipments of ELEVIDYS for non-ambulatory patients [6]. - The FDA issued a Safety Communication on June 24, 2025, confirming investigations into the deaths, causing an additional 8% drop in Sarepta's stock [7].